pCRP-mCRP Dissociation Mechanisms as Potential Targets for the Development of Small-Molecule Anti-Inflammatory Chemotherapeutics
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Circulating C-reactive protein (CRP) is a key acute-phase protein and one of the main clinical biomarkers for chronic inflammation. CRP is an important upstream mediator of inflammation and is associated with the onset of a number of important disease states including cardiovascular disease and neurodegenerative disorders such as Alzheimer’s disease. This pentraxin exerts pro-inflammatory properties via dissociation of the pentamer (pCRP) to a monomeric form (mCRP). This dissociation is induced by binding of pCRP to cell surface phosphocholine residues exposed by the action of phospholipase A2 (PLA2). Given the association of CRP with the onset of a range of serious disease states this CRP dissociation process is a tempting drug target for the development of novel small molecule therapeutics. This review will discuss potential targets for chemotherapeutic intervention elucidated during studies of CRP-mediated inflammation and provide an up to date summary of the development of small molecules, not only targeted directly at inhibiting conversion of pCRP to mCRP, but also those developed for activity against PLA2, given the key role of this enzyme in the activation of CRP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Black, S., Kushner, I., & Samols, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.r400025200 · Cited by 1,844
The physiological structure of human C-reactive protein and its complex with phosphocholine
Thompson, D., Pepys, M. B., & Wood, S. P. (1999) · Structure · doi:10.1016/s0969-2126(99)80023-9 · Cited by 818 · cited 3×
“Furthermore, effective binding of 10 indicates that the CRP active sites may tolerate phosphocholine analogs with larger, extended alkyl chains as has been indicated previously by the X-ray crystal structure of the CRP-phosphocholine complex (1).”
BackgroundInfluentialTargeting C-reactive protein for the treatment of cardiovascular disease.
Pepys, M. B., Hirschfield, G. M., Tennent, G. A., Ruth Gallimore, J., Kahan, M. C., Bellotti, V., Hawkins, P. N., Myers, R. M., Smith, M. D., Polara, A., et al. (2006) · Nature · doi:10.1038/nature04672 · Cited by 672 · cited 2×
“The only small molecule demonstrated to inhibit dissociation of pCRP to mCRP is the bis-phosphocholine dimer 1,6-bis (phosphocholine)-hexane (bis(PC)-H) 9 (22).”
BackgroundDarapladib for Preventing Ischemic Events in Stable Coronary Heart Disease
The STABILITY Investigators (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315878 · Cited by 579 · cited 1×
“Unfortunately, darapladib failed Phase III clinical trials due to a failure to alleviate the risk of cardiovascular death or stroke in coronary heart disease patients (43, 44).”
BackgroundSlevin, M., Matou, S., Zeinolabediny, Y., Corpas, R., Weston, R., Liu, D., Boras, E., Di Napoli, M., Petcu, E., Sarroca, S., et al. (2015) · Scientific Reports · doi:10.1038/srep13281 · Cited by 115 · cited 1×
“Furthermore, it has been shown there is an accumulation of mCRP in pertinent brain regions, arising from poststroke inflammation (17) and evidence that this observation explains the known link between ischemic stroke and onset of AD (18).”
BackgroundSelf-citationStrang, F., Scheichl, A., Chen, Y., Wang, X., Htun, N., Bassler, N., Eisenhardt, S. U., Habersberger, J., & Peter, K. (2012) · Brain Pathology · doi:10.1111/j.1750-3639.2011.00539.x · Cited by 94
Cited by
Tao, Q., Alvin Ang, T. F., Akhter-Khan, S. C., Itchapurapu, I. S., Killiany, R., Zhang, X., Budson, A. E., Turk, K. W., Goldstein, L., Mez, J., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012512 · Cited by 45
“There are 2 types of CRP: native CRP (pCRP) is a pentameric oligoprotein and acute-phase reactant that is produced during active inflammatory reaction,(5) and monomeric CRP (mCRP), or free subunits of pCRP, is produced during and after the acute phase by the irreversible dissociation of pCRP, which has much lower aque…”
BackgroundZhang, Z., Na, H., Gan, Q., Tao, Q., Alekseyev, Y., Hu, J., Yan, Z., Yang, J. B., Tian, H., Zhu, S., et al. (2021) · Aging Cell · doi:10.1111/acel.13501 · Cited by 45
Na, H., Yang, J. B., Zhang, Z., Gan, Q., Tian, H., Rajab, I. M., Potempa, L. A., Tao, Q., & Qiu, W. Q. (2023) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2023.02.013 · Cited by 27
Zhang, Z., Lin, W., Gan, Q., Lei, M., Gong, B., Zhang, C., Henrique, J. S., Han, J., Tian, H., Tao, Q., et al. (2024) · Angiogenesis · doi:10.1007/s10456-024-09946-4 · Cited by 10
“Monomeric C-reactive protein (mCRP) is released from pentameric CRP during the chronic stage of inflammation [17].”
Metadata
- Authors
- Caprio, V., Badimon, L., Di Napoli, M., Fang, W.-H., Ferris, G. R., Guo, B., Iemma, R. S., Liu, D., Zeinolabediny, Y., & Slevin, M.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2018-05-28
- Volume
- 9
- Pages
- 1089-1089
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2802594472
- Cited by
- 52
- References
- 6
- FWCI
- 1.57
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.